NeuroOne Medical Technologies Corporation has appointed Jason Mills to its Board of Directors, effective December 18, 2025. Mills currently serves as Executive Vice President of Strategy at Penumbra, Inc., where he leads long-range planning, financial planning and analysis, business development, and investor relations for the world's leading thrombectomy company.
Prior to his role at Penumbra, Mills spent over two decades as a dedicated medical technology investment analyst. He served as Managing Director and head of the medical technology equity research practice at Canaccord Genuity for more than 13 years, where he prepared financial models and forecasts, published research, and conducted due diligence on numerous public and private companies in the sector. His analytical work earned him recognition as the #2 ranked Medical Devices analyst in The Wall Street Journal's 2011 'Best on the Street' Survey and #1 in the Medical Products segment of Forbes 2010 Best Brokerage Analysts.
"We are privileged to welcome Jason to NeuroOne with his strong background in med-tech in both corporate settings and as an industry investment analyst," said Dave Rosa, CEO of NeuroOne. "Having known Jason since he was at Canaccord, I know he brings unparalleled and invaluable experience and insights in med-tech. His firsthand knowledge of our industry, combined with his investment and capital markets expertise, will be a critical resource as we progress on our clinical and corporate goals."
Paul Buckman, Chairman of the Board of Directors, noted that Mills will serve on the Compensation and Nominating & Corporate Governance Committees while helping the company expand its reach in transforming neurological disorder diagnosis and treatment. This appointment comes as NeuroOne develops and commercializes minimally invasive and hi-definition solutions for EEG recording, monitoring, ablation, drug delivery and stimulation for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other related neurological disorders.
The strategic implications of this board appointment are significant for business leaders and technology investors monitoring the medical technology sector. Mills brings both analytical rigor from his research background and operational experience from his current role at Penumbra, where he oversees strategic planning for a company addressing challenging medical conditions like ischemic stroke, venous thromboembolism, and acute limb ischemia. This combination of financial acumen and industry relationships positions NeuroOne to better navigate clinical development pathways, capital markets, and potential partnership opportunities.
For the broader medical technology industry, this move highlights the increasing value placed on leaders who can bridge the gap between clinical innovation and financial execution. As NeuroOne pursues applications in areas including depression, mood disorders, pain, incontinence, high blood pressure, and artificial intelligence, Mills' expertise could help accelerate the translation of neurological technologies from development to commercialization. The company's focus on improving patient outcomes while reducing procedural costs aligns with healthcare system priorities, making this leadership addition particularly relevant for stakeholders evaluating the future of neurological care innovation. More information about NeuroOne's technologies is available at https://nmtc1.com.
